Aditxt Introduces AditxtScore™ for COVID-19 and Announces the Completion of Validation Studies by Stanford Blood Center
AditxtScore™ for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens
Aditxt plans to file for an Emergency Use Authorization (EUA) followed by a 510(K) application with the U.S. Food and Drug Administration by the end of the current quarter (Q3, 2020).
Additionally, Aditxt is planning its operational capabilities in anticipation of beginning pilot programs utilizing AditxtScore™ for COVID-19 in Q4, 2020, with the goal of making AditxtScore™ commercially available starting in Q1, 2021.
finance.yahoo.com/news/aditxt-introduces-aditxtscore-covid-19-120000862.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1BRFRYJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAACikHVvS8-hGnPsTNgYnMzqpJCf9wNNteEpn3akLpPYWRBhfwD6TL1Y9dpjE6jAD5e2x1h9Oturcn3SIrluCfdzDR59tmBgoF3kjOPfQBhsdhRR77DHI3feh8k54XhytdhNlAp1AQwhM7Q4_-C0pdQ-9WoHHyTvrsx29ohL3B5_9&_guc_consent_skip=1596794102
AditxtScore™ for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens
Aditxt plans to file for an Emergency Use Authorization (EUA) followed by a 510(K) application with the U.S. Food and Drug Administration by the end of the current quarter (Q3, 2020).
Additionally, Aditxt is planning its operational capabilities in anticipation of beginning pilot programs utilizing AditxtScore™ for COVID-19 in Q4, 2020, with the goal of making AditxtScore™ commercially available starting in Q1, 2021.
finance.yahoo.com/news/aditxt-introduces-aditxtscore-covid-19-120000862.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1BRFRYJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAACikHVvS8-hGnPsTNgYnMzqpJCf9wNNteEpn3akLpPYWRBhfwD6TL1Y9dpjE6jAD5e2x1h9Oturcn3SIrluCfdzDR59tmBgoF3kjOPfQBhsdhRR77DHI3feh8k54XhytdhNlAp1AQwhM7Q4_-C0pdQ-9WoHHyTvrsx29ohL3B5_9&_guc_consent_skip=1596794102
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.